This cohort study assesses health care costs after initiating sacubitril-valsartan compared to an angiotensin-converting enzyme inhibitor or an angiotensin II receptor-blocker in Medicare patients being treated for heart failure with reduced ejection fraction. Here, ACE is linked to heart failure.